At a glance
- Originator Nonindustrial source
- Class Antiepileptic drugs; Antiparkinsonians; Neuroprotectants
- Mechanism of Action Glutamate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cognition disorders
Most Recent Events
- 27 Jun 2001 No-Development-Reported for Cognition disorders in Japan (Unknown route)
- 12 Mar 1996 Preclinical development for Cognition disorders in Japan (Unknown route)